JAZZ PHARMACEUTICALS FRANCE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2003-01-01

Employees: -

Market Cap: -

Website: https://www.jazzpharma.com/careers/open-positions/

Clinical Trials

A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: Sativex

First Posted Date: 2013-03-18

Last Posted Date: 2022-12-20

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 6

Registration Number: NCT01812603

Locations: 🇬🇧
Bristol Haematology & Oncology Centre, Bristol, United Kingdom
🇬🇧
St James's Institute of Oncology, St James's University Hospital, Leeds, Yorkshire, United Kingdom
🇬🇧
The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, United Kingdom

and more 2 locations

A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: Placebo
Drug: Sativex

First Posted Date: 2013-03-18

Last Posted Date: 2022-12-20

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 21

Registration Number: NCT01812616

Locations: 🇩🇪
Klinik für Onkologie, Hämatologie und Stammzelltransplantation, Universitätsklinikum Aachen RWTH, Aachen, Germany
🇩🇪
Neurologie des Klinikums Altenburger Land, Altenburg, Germany
🇩🇪
Zentrum für Neuroonkologie der Universität Duesseldorf, Duesseldorf, Germany

and more 8 locations

Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia

Phase 3

Completed

Conditions: High Risk Acute Myeloid Leukemia

Interventions: Drug: 7+3 (cytarabine and daunorubicin)
Drug: CPX-351

First Posted Date: 2012-09-28

Last Posted Date: 2020-08-10

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 309

Registration Number: NCT01696084

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 40 locations

A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy

Phase 2

Completed

Conditions: Narcolepsy

Interventions: Drug: ADX-N05
Drug: Placebo

First Posted Date: 2012-09-07

Last Posted Date: 2021-05-28

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 93

Registration Number: NCT01681121

Locations: 🇺🇸
The Center for Sleep and Wake Disorders, Chevy Chase, Maryland, United States
🇺🇸
Chicago Research Center, Chicago, Illinois, United States
🇺🇸
Washington University, Saint Louis, Missouri, United States

and more 25 locations

A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy

Phase 2

Completed

Conditions: Acute Lymphoblastic Leukemia
Lymphoblastic Lymphoma

Interventions: Drug: asparaginase Erwinia chrysanthemi

First Posted Date: 2012-07-18

Last Posted Date: 2021-06-23

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT01643408

Locations: 🇺🇸
John Hopkins, Baltimore, Maryland, United States
🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇨🇦
Hospital St. Justine, Saint Catherine, Quebec, Canada

and more 19 locations

A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis

Phase 3

Completed

Conditions: Multiple Sclerosis
Spasticity

Interventions: Drug: GW-1000-02

First Posted Date: 2012-06-04

Last Posted Date: 2023-01-10

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 137

Registration Number: NCT01610687

Locations: 🇬🇧
Rivermead Rehabilitation Centre, Oxford, United Kingdom

An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis

Phase 3

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: GW-1000-02

First Posted Date: 2012-06-04

Last Posted Date: 2023-01-10

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 154

Registration Number: NCT01610713

Locations: 🇬🇧
Rivermead Rehabilitation Centre, Oxford, United Kingdom

An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients

Phase 3

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Placebo
Drug: GW-1000-02

First Posted Date: 2012-06-04

Last Posted Date: 2023-01-12

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 160

Registration Number: NCT01610700

Locations: 🇬🇧
Rivermead Rehabilitation Centre, Oxford, United Kingdom

A Study of Cannabis Based Medicine Extracts and Placebo in Patients With Pain Due to Spinal Cord Injury

Phase 3

Completed

Conditions: Pain

Interventions: Drug: GW-1000-02
Drug: Placebo

First Posted Date: 2012-05-25

Last Posted Date: 2023-01-10

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 116

Registration Number: NCT01606202

Locations: 🇬🇧
The Royal National Orthopaedic Hospital, Middlesex, United Kingdom

A Study of the Long-term Safety of Sativex Use

Phase 3

Completed

Conditions: Multiple Sclerosis
Spasticity
Pain

Interventions: Drug: GW-1000-02

First Posted Date: 2012-05-25

Last Posted Date: 2023-05-06

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 507

Registration Number: NCT01606137

Locations: 🇬🇧
Gartnavel General Hospital, Glasgow, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy